Holen Sie sich die Stockscreener-App
0.00
100.00%
-6.75
Schlusskurs vom Vortag:
$6.75
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$26.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.67M
KGV:
0.00
EPS:
-3.09
Netto-Cashflow:
$-101.06M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$8.36
Athira Pharma Inc Stock (ATHA) Company Profile
Firmenname
Athira Pharma Inc
Sektor
Branche
Telefon
(425) 620-8501
Adresse
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare ATHA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.00 | 26.62M | 0 | -117.67M | -101.06M | -3.09 |
VRTX
Vertex Pharmaceuticals Inc
|
446.18 | 115.27B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.89 | 80.00B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
695.99 | 43.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
325.29 | 43.52B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
285.05 | 30.74B | 5.36B | 287.73M | 924.18M | 2.5229 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-09-19 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-09-04 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-09-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-10-17 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-06-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | Herabstufung | Jefferies | Buy → Hold |
| 2022-06-23 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Eingeleitet | BTIG Research | Buy |
| 2022-04-21 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Goldman | Neutral |
| 2020-10-13 | Eingeleitet | Goldman | Buy |
| 2020-10-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-13 | Eingeleitet | Jefferies | Buy |
| 2020-10-13 | Eingeleitet | Stifel | Buy |
Alle ansehen
Athira Pharma Inc Aktie (ATHA) Neueste Nachrichten
LeonaBio Updates Investors on 2025 Results and Strategy - TipRanks
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update - Bitget
LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug - Stock Titan
Momentum Shift: Can Athira Pharma Inc be recession proof2026 Pullback Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Contrasting Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME) - Defense World
What dividend growth rate does Athira Pharma Inc offer2026 Short Interest & Accurate Intraday Trading Signals - baoquankhu1.vn
LeonaBio shareholders approve equity plan and increase in authorized shares - Investing.com India
LeonaBio (ATHA) wins approval for 2026 equity plan and major share increase - Stock Titan
Published on: 2026-03-20 02:58:44 - baoquankhu1.vn
Risk Report: Can Athira Pharma Inc ride the EV wave2026 Macro Impact & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Earnings Miss: Is Athira Pharma Inc subject to activist investor interest2026 Trading Volume Trends & Trade Opportunity Analysis Reports - baoquankhu1.vn
Athira Pharma shares surge after securing rights to phase 3 breast cancer therapy - MSN
Shorts Report: Can Athira Pharma Inc be recession proofEarnings Risk Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Top Athira Pharma (LONA) Competitors 2026 - MarketBeat
[DEFR14A] LeonaBio, Inc. Revised Proxy Statement - Stock Titan
Reviewing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Reviewing Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN) - Defense World
Sentiment Review: Is Athira Pharma Inc subject to activist investor interest2025 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn
Should I invest in Athira Pharma Inc before earningsPortfolio Risk Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
LeonaBio CEO Litton sells $27,687 in shares By Investing.com - Investing.com India
LeonaBio CEO Litton sells $27,687 in shares - Investing.com South Africa
Renninger, LeonaBio CFO, sells $4.9k in LONA stock - Investing.com Australia
LeonaBio (ATHA) CEO converts 22,254 RSUs and sells shares for taxes - Stock Titan
LeonaBio (LONA) CMO covers RSU tax bill with share sale - Stock Titan
LeonaBio (NASDAQ: ATHA) files to sell 22,254 shares after RSU lapse - Stock Titan
Athira Pharma (LONA) Stock Forecast and Price Target 2026 $LONA - MarketBeat
Comparing Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME) - Defense World
Breakout Watch: Whats the beta of Athira Pharma Inc stockSwing Trade & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Financial Contrast: Athira Pharma (NASDAQ:LONA) vs. Prime Medicine (NASDAQ:PRME) - Defense World
Athira Pharma (LONA) 10K Form and SEC Filings 2026 $LONA - MarketBeat
Athira Pharma (NASDAQ:LONA) versus Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Analysis - Defense World
Athira Pharma (NASDAQ:LONA) Now Covered by Analysts at Cantor Fitzgerald - Defense World
Cantor Fitzgerald initiates Leona Bio stock with overweight rating By Investing.com - Investing.com Australia
Cantor Fitzgerald initiates Leona Bio stock with overweight rating - Investing.com UK
Reviewing Prime Medicine (NASDAQ:PRME) and Athira Pharma (NASDAQ:LONA) - Defense World
Analyzing Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME) - Defense World
Critical Analysis: Liminatus Pharma (NASDAQ:LIMN) and Athira Pharma (NASDAQ:LONA) - Defense World
Analyzing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME) Financial Review - Defense World
ATHA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BML Capital Management LLC Has $1.34 Million Stock Position in Athira Pharma, Inc. $ATHA - Defense World
LeonaBio Shares Rise After Mizuho Securities Upgrade - marketscreener.com
Mizuho upgrades LeonaBio stock rating on breast cancer drug potential By Investing.com - Investing.com Canada
Head-To-Head Contrast: Alterity Therapeutics (NASDAQ:ATHE) & Athira Pharma (NASDAQ:ATHA) - Defense World
Athira Pharma (NASDAQ:LONA) Upgraded at Wall Street Zen - Defense World
Can Athira Pharma Inc. expand into new markets2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Athira Pharma (LONA) Stock Trends and Sentiment 2026 $LONA - MarketBeat
LONA News Today | Why did Athira Pharma stock drop today? - MarketBeat
Athira Pharma (LONA) Stock Price, News & Analysis $LONA - MarketBeat
Athira Pharma (LONA) Stock Chart and Price History 2026 $LONA - MarketBeat
Finanzdaten der Athira Pharma Inc-Aktie (ATHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Athira Pharma Inc-Aktie (ATHA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Litton Mark James | PRESIDENT and CEO |
Mar 04 '26 |
Sale |
5.37 |
5,156 |
27,688 |
57,926 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
3,900 |
0 |
16,757 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
906 |
4,865 |
15,851 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 03 '26 |
Option Exercise |
0.00 |
5,726 |
0 |
19,704 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 04 '26 |
Sale |
5.37 |
1,328 |
7,131 |
18,376 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
5,856 |
0 |
26,537 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,359 |
7,298 |
25,178 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
7,418 |
0 |
17,607 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,720 |
9,236 |
15,887 |
0.93%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):